Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

NCT04706598 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Urinary Bladder Neoplasms
Immunotherapy

Interventions

DRUG: Camrelizumab

Sponsor

Fudan University

Collaborators

[object Object]